Laetitia Daubisse-Marliac1, Marc Colonna2, Brigitte Trétarre3, Gautier Defossez4, Florence Molinié5, Karine Jéhannin-Ligier6, Emilie Marrer7, Pascale Grosclaude8. 1. Claudius Regaud Institute, Regional Cancer Center, IUCT-O, Tarn Cancer Registry, Toulouse, F-31059, France; CHU, Toulouse F-31000, France; LEASP, UMR 1027 Inserm, Toulouse III University, F-31000, France; FRANCIM Network, Toulouse, F-31073, France. Electronic address: laetitia.daubisse-marliac@inserm.fr. 2. FRANCIM Network, Toulouse, F-31073, France; Isère Cancer Registry, Grenoble, F-38043, France. Electronic address: mcolonna.registre@wanadoo.fr. 3. FRANCIM Network, Toulouse, F-31073, France; Hérault Cancer Registry, Regional Cancer Center (ICM), Montpellier, F-34000, France. Electronic address: REGISTRE-TUMEUR@wanadoo.fr. 4. FRANCIM Network, Toulouse, F-31073, France; Poitou-Charentes Cancer Registry, CHU Poitiers, F-86000, France. Electronic address: gautier.defossez@univ-poitiers.fr. 5. FRANCIM Network, Toulouse, F-31073, France; Loire-Atlantique & Vendée Cancer Registry, CHU Nantes, F-44000, France. Electronic address: florence.molinie@chu-nantes.fr. 6. FRANCIM Network, Toulouse, F-31073, France; Cancer Registry of Lille, C2RC, Lille, F-59000, France. Electronic address: kligier@registrecancers59.fr. 7. FRANCIM Network, Toulouse, F-31073, France; Haut-Rhin Cancer Registry, ARER 68 Mulhouse, F-68000, France. Electronic address: emilie.marrer@ghrmsa.fr. 8. Claudius Regaud Institute, Regional Cancer Center, IUCT-O, Tarn Cancer Registry, Toulouse, F-31059, France; LEASP, UMR 1027 Inserm, Toulouse III University, F-31000, France; FRANCIM Network, Toulouse, F-31073, France. Electronic address: pascale.grosclaude@inserm.fr.
Abstract
BACKGROUND: Penile cancer is rare, and few population-based studies have described changes in time trend. This study aims to determine whether there has been an evolution in incidence and survival of penile cancer over time in France. METHODS: Rates of age world-standardized incidence (ASRW) and net survival (NS) between 1989 and 2011 were calculated using data from 16 French cancer registries. Time trend incidence and survival analysis were confined to the eight registries operating throughout the full period. Log-linear Poisson regression analysis was used to estimate the average annual percentage change (AAPC) in incidence rates. The incidence rate for the most recent period was also calculated from all 16 cancer registries operating during 2009-2011. Human papillomavirus (HPV) exposure was deduced from the morphological code. NS was estimated using the Pohar-Perme estimator of the net cumulative rate. RESULTS: No significant change in incidence was observed between 1989 and 2011 (AAPC: 0.08%; 95%CI: -1.01%; +1.17%). The incidence increased with age. The ASRW in 16 registries operating in 2009-2011 was 0.59 per 100,000 (95%CI: 0.50-0.68). The proportion of cases potentially linked to HPV was nearly 11% and did not change significantly over time. NS decreased with age but did not change over time (around 65% at 5 years). CONCLUSION: Penile cancer remains rare in France, but survival is still low - probably because of delays in diagnosis and limited improvements in care. International clinical trials are needed to develop care recommendations based on an adequate level of evidence.
BACKGROUND:Penile cancer is rare, and few population-based studies have described changes in time trend. This study aims to determine whether there has been an evolution in incidence and survival of penile cancer over time in France. METHODS: Rates of age world-standardized incidence (ASRW) and net survival (NS) between 1989 and 2011 were calculated using data from 16 French cancer registries. Time trend incidence and survival analysis were confined to the eight registries operating throughout the full period. Log-linear Poisson regression analysis was used to estimate the average annual percentage change (AAPC) in incidence rates. The incidence rate for the most recent period was also calculated from all 16 cancer registries operating during 2009-2011. Human papillomavirus (HPV) exposure was deduced from the morphological code. NS was estimated using the Pohar-Perme estimator of the net cumulative rate. RESULTS: No significant change in incidence was observed between 1989 and 2011 (AAPC: 0.08%; 95%CI: -1.01%; +1.17%). The incidence increased with age. The ASRW in 16 registries operating in 2009-2011 was 0.59 per 100,000 (95%CI: 0.50-0.68). The proportion of cases potentially linked to HPV was nearly 11% and did not change significantly over time. NS decreased with age but did not change over time (around 65% at 5 years). CONCLUSION:Penile cancer remains rare in France, but survival is still low - probably because of delays in diagnosis and limited improvements in care. International clinical trials are needed to develop care recommendations based on an adequate level of evidence.
Authors: Xinxi Deng; Yang Liu; Xiangpeng Zhan; Tao Chen; Ming Jiang; Xinhao Jiang; Luyao Chen; Bin Fu Journal: Front Oncol Date: 2022-06-17 Impact factor: 5.738
Authors: Isabelle Antwerpen; Lukas Gstrein; Linda Moskovszky; Hans Martin Gissler; Tilmann Möltgen; Maciej Kwiatkowski; Stephen Wyler; Matthias Walter Journal: J Int Med Res Date: 2018-12-05 Impact factor: 1.671
Authors: Juan Chipollini; Grant Pollock; Chiu-Hsieh Hsu; Ken Batai; Alejandro Recio-Boiles; Benjamin R Lee Journal: Cancer Med Date: 2021-10-10 Impact factor: 4.452
Authors: Silvia Regina Rogatto; Igor Tsaur; Anita Thomas; Luisa Matos do Canto Alvim; Claudia Aparecida Rainho; Eva Juengel; Roman Alexander Blaheta; Philippe E Spiess Journal: Transl Androl Urol Date: 2021-10